The story of Sildenafil presents a challenging picture for those considering investment. While the initial launch generated substantial returns, the end of its exclusive rights opened the door to off-brand versions, https://yesbookmarks.com/story21727219/the-copyright-and-the-pharmaceutical-industry-a-risky-opportunity